Request Demo
Last update 14 Jun 2025
GNC-077
Last update 14 Jun 2025
Overview
Basic Info
Drug Type Tetraspecific antibody |
Synonyms GNC 077, GNC077 |
Target |
Action stimulants |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with GNC-077NCT06755242
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT06609187
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
CTR20243595
评估 GNC-077 多特异性抗体注射液在局部晚期或转移性乳腺癌及其他实体瘤患者中的安全性、耐受性、药代动力学/药效动力学及抗肿瘤活性的开放性、多中心、I 期临床研究
[Translation] An open-label, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and anti-tumor activity of GNC-077 multispecific antibody injection in patients with locally advanced or metastatic breast cancer and other solid tumors
100 Clinical Results associated with GNC-077
Login to view more data
100 Translational Medicine associated with GNC-077
Login to view more data
100 Patents (Medical) associated with GNC-077
Login to view more data
100 Deals associated with GNC-077
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gastrointestinal Neoplasms | Phase 1 | China | 01 Jan 2025 | |
| Locally advanced breast cancer | Phase 1 | China | 30 Oct 2024 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 16 Oct 2024 | |
| Colorectal Cancer | IND Approval | China | 20 Sep 2024 | |
| Esophageal Carcinoma | IND Approval | China | 20 Sep 2024 | |
| Nasopharyngeal Carcinoma | IND Approval | China | 20 Sep 2024 | |
| Small Cell Lung Cancer | IND Approval | China | 20 Sep 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free